2016~2018年南京地区50家医院免疫调节药物使用调查  

Investigation on Usage and Trend of Immunomodulatory Drugs in 50 Hospitals in Nanjing District During 2016-2018

作　　者：姚瑶[1] 刘慧[1] 戴惠珍[2] 葛卫红[1] Yao Yao;Liu Hui;Dai Huizhen;Ge Weihong(Department of pharmacy,Nanjing University Affiliated Drum Tower Hospital,Nanjing 210008,China;Jiangsu Institute of Medical Information)

机构地区：[1]南京大学医学院附属鼓楼医院药学部,南京210008 [2]江苏省医药情报研究所

出　　处：《药物流行病学杂志》2020年第8期552-555,569,共5页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:了解近年南京地区免疫调节药物的应用情况和趋势,为临床合理使用免疫调节药物提供参考。方法:依据江苏省医药情报研究所提供的数据,分别统计和计算2016~2018年南京地区50家医院免疫调节药物的销售金额、用药频度(DDDs)、限定日费用(DDC)、排序比等指标,并分析用药趋势。结果:2016~2018年南京地区50家医院免疫调节药物销售金额呈逐年下降趋势,免疫增强药下降更显著。免疫抑制药销售金额排名前3位的是他克莫司、吗替麦考酚酯和环孢素;DDDs排名前3位的是雷公藤总苷、他克莫司和吗替麦考酚酯,2018年艾拉莫德DDDs排名升至第二;免疫抑制药排序比为0.5~4。乌司他丁和匹多莫德等免疫增强药销售金额上升明显;羧甲基淀粉钠、川黄口服液和参麦注射液DDDs排名连续3年位居前四,白细胞介素-2DDDs下降较多;免疫增强药排序比为0.1~9。三级医院为免疫调节药物主要使用者,但2017年开始,二级及以下医院免疫调节药物使用逐渐增多。结论:南京地区免疫调节药物的使用基本符合患者的用药需求,其中免疫增强药用量逐年下降,与其使用合理性增加有关。Objective:To understand the latest application and trends of immunomodulatory drugs in Nanjing district and provide reference for the rational use of immunomodulatory drugs in clinic. Methods:Sales amount, defined daily dose system(DDDs), drug daily cost(DDC) and ranking ratio of immunomodulatory drugs in 50 Nanjing hospitals over the past three years was analyzed to reveal the trend of drug use, according to the data of immunomodulatory drugs in Nanjing from 2016 to 2018 provided by Jiangsu provincial institute of medical information. Results:The sales amount of immunomodulatory drugs decreased year by year from 2016 to 2018, and the decrease of immunomodulatory enhancers was more significant. The top three drugs in terms of sales of immunosuppressants were tacrolimus, mycophenolate and cyclosporin, while the top three drugs of DDDs were tripterygium, tacrolimus and mycophenolate. It is worth mentioning that iguratimod DDDs moved up to the second place in 2018. The ranking ratio of immunosuppressive drugs was between 0.5 and 4. There was major changes in the sale amount of immunoenhancing drug from 2016 to 2018. The sale amount of ulinastatin and pidomode rose significantly. Carboxymethyl starch sodium chuanhuang oral liquid and shenmai injection DDDs ranked in the top four for three consecutive years, while DDDs of interleukin-2 decreased significantly. The ranking ratio of immunoenhancing drugs was between 0.1 and 9. Tertiary hospitals were the main users of immunomodulatory drugs. But since 2017, immunomodulatory drugs had been increasingly used in community hospitals. Conclusion:The use of immunomodulatory drugs in Nanjing basically meets the needs of patients. The use of immune-enhancing drugs decreased over the three years, which was related to the rationality of medication.

关 键 词：免疫调节药物 用药频度 限定日费用 排序比 药物利用 

分 类 号：F407.7[经济管理—产业经济]